Table 1.
Change from baseline in EORTC QLQ-C30 GHS/QOL symptom scores and EORTC QLQ-STO22 symptom subscale scores at week 18
| Treatment | Baseline score, mean (SD) | Week 18 score, mean (SD) | Change from baseline at week 18, LSM (95% CI)a | Difference in LSM (95% CI) |
|---|---|---|---|---|
| EORTC QLQ-C30 GHS/QOL | ||||
| Pembrolizumab |
n = 239 62.7 (21.8) |
n = 102 66.4 (20.2) |
n = 251 −1.9 (−5.8 to 2.0) |
−0.16 (−5.0 to 4.7) P = 0.948 |
| Chemotherapy |
n = 234 62.4 (21.1) |
n = 140 63.6 (20.2) |
n = 243 −1.8 (−5.2 to 1.7) |
|
| EORTC QLQ-C30 nausea/vomiting | ||||
| Pembrolizumab |
n = 239 16.1 (21.9) |
n = 102 15.9 (23.3) |
n = 251 5.8 (1.3-10.3) |
−2.1 (−7.8 to 3.7) P = 0.477 |
| Chemotherapy |
n = 234 16.8 (21.9) |
n = 140 21.2 (25.2) |
n = 243 7.9 (4.0-11.8) |
|
| EORTC QLQ-C30 appetite loss | ||||
| Pembrolizumab |
n = 239 33.9 (33.9) |
n = 102 21.9 (29.1) |
n = 251 −3.5 (−9.4 to 2.3) |
−4.6 (−11.9 to 2.7) P = 0.217 |
| Chemotherapy |
n = 234 36.6 (33.3) |
n = 140 32.9 (30.7) |
n = 243 1.0 (−4.1 to 6.2) |
|
| EORTC QLQ-STO22 pain | ||||
| Pembrolizumab |
n = 239 30.4 (22.1) |
n = 102 22.0 (20.2) |
n = 251 −1.1 (−4.7 to 2.4) |
2.4 (−2.2 to 6.9) P = 0.308 |
| Chemotherapy |
n = 233 28.8 (21.3) |
n = 139 22.3 (20.4) |
n = 243 −3.5 (−6.6 to −0.4) |
|
CI, confidence interval; GHS, global health status; LSM, least squares mean; EORTC QLQ-C30, European Organisation for the Research and Treatment of Cancer core 30 quality-of-life questionnaire; EORTC QLQ-STO22, European Organisation for the Research and Treatment of Cancer 22-question quality-of-life gastric cancer-specific module; QOL, quality of life; SD, standard deviation.